OverviewSuggest Edit

Crescendo Biologics is a provider of human VH antibody fragment therapeutics created to optimize antibodies and a transgenic mouse which produces heavy chain only antibodies. The Company develops potent, multi-functional Humabody, therapeutics in oncology with a proprietary pipeline focus on CB307, a unique targeted T-cell engager. It uses its VH fragment discovery platform to advance in-house development programs in inflammation and oncology, using transgenic mice.

TypePrivate
Founded2007
HQBabraham, GB
Websitecrescendobiologics.com

Latest Updates

Employees (est.) (Sept 2021)37(-5%)
Revenue (FY, 2018)£7.5 M(+316%)
Cybersecurity ratingBMore

Key People/Management at Crescendo Biologics

Philip Bland-Ward

Philip Bland-Ward

CDO
Theodora Harold

Theodora Harold

CEO and Director
Kevin Johnson

Kevin Johnson

Chairman
Julia Tilson

Julia Tilson

COO
Graziano Seghezzi

Graziano Seghezzi

Non-Executive Director
Richard Williams

Richard Williams

SVP CMC and Development
Show more

Crescendo Biologics Office Locations

Crescendo Biologics has an office in Babraham
Babraham, GB (HQ)
Meditrina Building 260 Babraham Research Campus
Show all (1)

Crescendo Biologics Financials and Metrics

Summary Metrics

Founding Date

2007

Crescendo Biologics total Funding

$116.2 m

Crescendo Biologics latest funding size

$70 m

Time since last funding

3 years ago

Crescendo Biologics investors

Crescendo Biologics's latest funding round in April 2018 was reported to be $70 m. In total, Crescendo Biologics has raised $116.2 m
Show all financial metrics

Crescendo Biologics Revenue

Embed Graph
View revenue for all periods
Crescendo Biologics's revenue was reported to be £7.51 m in FY, 2018
GBP

Revenue (FY, 2018)

7.5m

Gross profit (FY, 2018)

7.5m

Gross profit margin (FY, 2018), %

100%

Net income (FY, 2018)

(1.8m)

EBIT (FY, 2018)

(2.2m)

Cash (31-Dec-2018)

24.8m
GBPFY, 2016FY, 2017FY, 2018

Revenue

758.3k1.8m7.5m

Gross profit

758.3k1.8m7.5m

Gross profit Margin, %

100%100%100%
GBPFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

2.3m894.8k2.1m331.6k3.0m2.7m4.3m7.0m24.8m

Accounts Receivable

530.0k704.1k

Current Assets

2.4m950.9k2.9m766.0k6.2m10.7m5.8m9.8m28.5m
GBPFY, 2015FY, 2016FY, 2017FY, 2018

Cash From Operating Activities

(5.2m)(4.7m)(7.2m)167.3k

Cash From Investing Activities

(4.9m)(175.1k)(365.2k)(418.3k)

Cash From Financing Activities

9.8m3.9k18.1m

Net Change in Cash

(321.9k)(4.9m)(7.6m)17.8m
Show all financial metrics

Crescendo Biologics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Crescendo Biologics Online and Social Media Presence

Embed Graph

Crescendo Biologics News and Updates

Invitation du Dr James Legg, vice-président de la recherche et du développement chez Crescendo Biologics et président de la conférence d'immuno-oncologie de cette année

LONDRES, August 23, 2018 /PRNewswire/ -- La conférence d'immuno-oncologie de 2018 de SMi se déroulera à Londres, au Royaume-Uni, le 26 et le 27 septembre. Elle offrira aux participants l'occasion inédite de venir écouter des experts renommés qui leur feront part de leur expertise et de...

Crescendo Biologics Blogs

Crescendo Biologics announces initiation of Phase 1 study of CB307 in patients with advanced, PSMA-positive solid tumours

Crescendo Biologics announces initiation of Phase 1 study of CB307 in patients with advanced, PSMA-positive solid tumours View PDF The post Crescendo Biologics announces initiation of Phase 1 study of CB307 in patients with advanced, PSMA-positive solid tumours appeared first on Crescendo Biologics.

Crescendo Biologics further strengthens leadership team with appointment of Dr Michael Booth as Chief Financial Officer

Crescendo Biologics further strengthens leadership team with appointment of Dr Michael Booth as Chief Financial Officer View PDF The post Crescendo Biologics further strengthens leadership team with appointment of Dr Michael Booth as Chief Financial Officer appeared first on Crescendo Biologics.

Crescendo Biologics and IAG partner to support the clinical development of CB307 with advanced imaging analysis technology

Crescendo Biologics and IAG partner to support the clinical development of CB307 with advanced imaging analysis technology View PDF The post Crescendo Biologics and IAG partner to support the clinical development of CB307 with advanced imaging analysis technology appeared first on Crescendo Biologic…

New data demonstrate that Humabodies® are highly effective in generating monospecific and bispecific CAR-T cells to target solid tumours

New data demonstrate that Humabodies® are highly effective in generating monospecific and bispecific CAR-T cells to target solid tumours View... The post New data demonstrate that Humabodies® are highly effective in generating monospecific and bispecific CAR-T cells to target solid tumours appeared…

Unlocking the potential of PSMA as a cancer target

Unlocking the potential of PSMA as a cancer target MedNous
Show more

Crescendo Biologics Frequently Asked Questions

  • When was Crescendo Biologics founded?

    Crescendo Biologics was founded in 2007.

  • Who are Crescendo Biologics key executives?

    Crescendo Biologics's key executives are Philip Bland-Ward, Theodora Harold and Kevin Johnson.

  • How many employees does Crescendo Biologics have?

    Crescendo Biologics has 37 employees.

  • What is Crescendo Biologics revenue?

    Latest Crescendo Biologics annual revenue is £7.5 m.

  • What is Crescendo Biologics revenue per employee?

    Latest Crescendo Biologics revenue per employee is £202.9 k.

  • Who are Crescendo Biologics competitors?

    Competitors of Crescendo Biologics include AbCellera Biologics, Refuge Biotechnologies and Tmunity Therapeutics.

  • Where is Crescendo Biologics headquarters?

    Crescendo Biologics headquarters is located at Meditrina Building 260 Babraham Research Campus, Babraham.

  • Where are Crescendo Biologics offices?

    Crescendo Biologics has an office in Babraham.

  • How many offices does Crescendo Biologics have?

    Crescendo Biologics has 1 office.